Tango Therapeutics TNGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$107.23M+18.9% | -$101.59M+22.0% | -$100.52M+18.5% | -$145.57M-25.0% | -$132.26M-18.5% | ||
| $2.12M-15.0% | $2.28M-8.7% | $2.42M-3.0% | $2.49M+0.1% | $2.5M+1.5% | ||
| $29.97M+1.8% | $26.43M-8.5% | $27.91M+6.1% | $28.47M+18.6% | $29.43M+36.4% | ||
| -$141.55M-4.6% | -$138.89M-5.6% | -$145.82M-19.2% | -$148.25M-23.5% | -$135.34M-11.9% | ||
| $995K+63.1% | $1.05M+39.0% | $950K+11.0% | $914K+20.7% | $610K-44.6% | ||
| -$61.83M-148% | -$40.87M-147% | $146.91M+116% | $132.01M— | $127.93M— | ||
| $302.34M+6,355% | $222.5M+367% | $4.09M-91.5% | $3.95M-96.9% | $4.68M-96.3% | ||
| $98.97M+3,724% | $42.75M+1,768% | $5.19M+183% | -$12.29M+19.9% | -$2.73M-189% | ||
| -$142.55M-4.9% | -$139.93M-5.8% | -$146.77M-19.1% | -$149.17M-23.5% | -$135.95M-11.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's cash flow data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.